81 search results for: asthma

ADVENT at ERS 2024
Congress
7
September
2024
Congress
ADVENT at ERS 2024

The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.

Celeste Porsbjerg
Expert
Celeste Porsbjerg, MD, PhD

Professor of Severe Asthma, Bispebjerg Hospital Copenhagen, Denmark

Nicole Chase
Expert
Nicole Chase, MD

Associate Professor of Medicine, University of Minnesota; Physician Minneapolis VA Health Care System; Partner, St. Paul Allergy & Asthma, PA

Event Thumbnail
Congress
24
October
2025
Congress
ADVENT at EAACI PAAM 2025

Join Sanofi and Regeneron for ​an educational symposium on type 2 inflammation processes underlying pediatric asthma, atopic dermatitis,​ and eosinophilic esophagitis.

Simon Couillard
Expert
Simon Couillard, MD, MSc

Professor Couillard is a respirologist and the Québec Lung Association Chair of Respiratory Research at the Université de Sherbrooke, Canada. He leads a team investigating ways to use biomarkers to predict and prevent asthma attacks and improve asthma management.

Njira Lugogo
Expert
Njira Lugogo, MD

Dr. Lugogo is a Professor of Medicine in the Division of Pulmonary, Critical Care Medicine and is the Director of the Michigan Medicine Asthma Program. She is also the Program Director of INHALE, a statewide collaborative quality improvement program that focuses on improving the care of patients with asthma and COPD in Michigan.

How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
On Demand
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.

Miguel Lanz
Expert
Miguel Lanz, MD, FAAAAI

Lanz Allergy, Asthma & Immunology AAADRS Clinical Research Center | Coral Gables, FL

G. Walter Canonica
Expert
G. Walter Canonica, MD

Head of Personalized Medicine Center, Asthma and Allergy | Humanitas Research Hospital, Milan, Italy

Enrico Heffler
Expert
Enrico Heffler, MD, PhD

Associate Professor of Internal Medicine and Consultant | Personalized Medicine Asthma and Allergy Unit, Humanitas University, Milan, Italy

Theresa Guilbert
Expert
Theresa Guilbert, MD, MS

Professor | University of Cincinnati; Director of the Asthma Center | Cincinnati Children’s Hospital Medical Center, Ohio, United States

Leonard Bacharier
Expert
Leonard Bacharier, MD

Janie Robinson and John Moore Lee Chair of Pediatrics and Director of Center for Pediatric Asthma Research | Vanderbilt University, Tennessee, United States